Interim Analysis Expected End of 2Q 2025BETHESDA, MD, Mar 14, 2025 - (ACN Newswire) - Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading ...
This overview is a glance at major phase I, phase II, phase III and phase IV clinical trial phases that are considered potentially ... leave the PharmiWeb.com website and will be redirected to another ...
Find out what led biotech to a situation where women are underrepresented in clinical trials and how the industry is ...
AL002 misses Phase 2 goal in early Alzheimer's. Key Phase 3 data for latozinemab in 2025. Click here to read why ALEC is a ...
AskBio Inc., a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, has announced the ...
This may have important implications for drug development and clinical ... another author. "Just the same, your odds are dramatically better than they would be for a Phase I trial." ...
After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the ...
The VER-01 therapy – a cannabis extract that includes the full range of cannabinoid compounds including low levels of THC – was effective as a treatment for chronic lower back pain in a pair of ...
According to the National Institutes of Health, between 600,000 and 900,000 Americans have ulcerative colitis, a chronic ...
“Dosing the first participant in the second cohort of the trial is positive news for people living with LGMD2I/R9. This is a rare and debilitating type of muscular dystrophy, and this advancement ...
Q4 2024 Earnings Call Transcript March 5, 2025 EyePoint Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.64 EPS, expectations were $-0.54. Tessa Romero – JPMorgan: Yigal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback